ALK – Epidemiology – Mature Markets Data

Clarivate Epidemiology’s coverage of anaplastic lymphoma kinase- (ALK)-mutated cancers comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of ALK-mutated cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s ALK-mutated cancer forecast will answer the following questions:

  • Of all people with ALK-mutated cancer, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people with ALK-mutated cancer, how many in each of the major mature pharmaceutical markets are drug-treatable?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALK-mutated cancer over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 44 ALK-mutated cancer populations, including the following:

  • Incident cases of ALK-mutated cancer by primary tumor site.
  • Incident cases of ALK-mutated cancer by metastatic status.
  • First-line drug-treatable population of ALK-mutated cancer by site of primary tumor.

Note: Coverage may vary by country.